Company News: Lilly and Incyte
Eli Lilly forged a deal with Incyte, gaining rights to develop and globally commercialize Incyte's oral JAK1/JAK2 inhibitor, INCB28050, and ...
Your Email Address: *
Recipient(s) Email Address: *
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
The e-mail address(es) that you supply to use this service will only be used to send the requested article.